Insider Trading Alert - ILMN, CMPR And UTEK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 19, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,088.06 to $96,569,200.00.

Highlighted Stocks Traded by Insiders:

Illumina (ILMN) - FREE Research Report

Naclerio Nicholas, who is Sr VP, Corporate Development at Illumina, sold 6,590 shares at $199.16 on May 19, 2015. Following this transaction, the Sr VP, Corporate Development owned 34,867 shares meaning that the stake was reduced by 15.9% with the 6,590-share transaction.

The shares most recently traded at $200.95, up $1.79, or 0.89% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 24,270
  • 12-Week # shares sold: 107,787
  • 24-Week # shares sold: 198,252

The average volume for Illumina has been 1.1 million shares per day over the past 30 days. Illumina has a market cap of $28.9 billion and is part of the health care sector and drugs industry. Shares are up 9.51% year-to-date as of the close of trading on Tuesday.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 69.5. Currently, there are 12 analysts who rate Illumina a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Illumina Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cimpress (CMPR) - FREE Research Report

Blake Katryn, who is Pres, Vistaprint Business Unit at Cimpress, sold 2,013 shares at $84.94 on May 19, 2015. Following this transaction, the Pres, Vistaprint Business Unit owned 19,121 shares meaning that the stake was reduced by 9.52% with the 2,013-share transaction.

The shares most recently traded at $84.76, down $0.18, or 0.21% since the insider transaction. Historical insider transactions for Cimpress go as follows:

  • 4-Week # shares sold: 747
  • 12-Week # shares sold: 8,352
  • 24-Week # shares sold: 14,583

The average volume for Cimpress has been 235,900 shares per day over the past 30 days. Cimpress has a market cap of $2.8 billion and is part of the services sector and diversified services industry. Shares are up 12.44% year-to-date as of the close of trading on Tuesday.

Vistaprint N.V. operates as an online supplier of coordinated portfolios of marketing products and services to micro businesses worldwide. The company has a P/E ratio of 29.6. Currently, there are no analysts who rate Cimpress a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMPR - FREE

TheStreet Quant Ratings rates Cimpress as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Cimpress Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ultratech (UTEK) - FREE Research Report

Wright Bruce R, who is Sr. VP-Fin, CFO & Secretary at Ultratech, sold 20,000 shares at $20.59 on May 19, 2015. Following this transaction, the Sr. VP-Fin, CFO & Secretary owned 144,572 shares meaning that the stake was reduced by 12.15% with the 20,000-share transaction.

The shares most recently traded at $20.37, down $0.22, or 1.1% since the insider transaction. Historical insider transactions for Ultratech go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 10,000

The average volume for Ultratech has been 249,200 shares per day over the past 30 days. Ultratech has a market cap of $566.4 million and is part of the technology sector and electronics industry. Shares are up 10.13% year-to-date as of the close of trading on Tuesday.

Ultratech, Inc. develops, manufactures, and markets photolithography, laser thermal processing, and inspection equipment. It supplies step-and-repeat photolithography systems based on one-to-one imaging technology for semiconductor device and nanotechnology manufacturers. Currently, there are 5 analysts who rate Ultratech a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UTEK - FREE

TheStreet Quant Ratings rates Ultratech as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Ultratech Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday

Stocks Move Lower on Trade Fears and 4 Other Stories You Must Know Wednesday

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Target Slumps After Q1 Earnings Miss as Comparable Sales Slow, Traffic Improves

Target Slumps After Q1 Earnings Miss as Comparable Sales Slow, Traffic Improves

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes

Pound Slides as Inflation Slows, Doubts Grow Over Bank of England Rate Hikes